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Anthocyanins and anthocyanidins are poor inhibitors of CYP2D6
Abstract
The cytochrome P450 CYP2D6 isoform is involved in the metabolism of about 50% of all psychoactive
drugs, including neuroleptic agents, selective serotonin reuptake inhibitors, selective norepinephrine
reuptake inhibitors and tricyclic antidepressants. Therefore, inhibition of cytochrome P450 activity by
foodstuffs has implications for drug safety. The present study addresses inhibitory effects of
polyphenolic anthocyanins and their aglycons that are found in many dietary fruits and vegetables.
Using a chemiluminescent assay, we obtained IC(50) values ranging from 55 microM to > 800 microM
for 17 individual compounds. According to earlier data on furanocoumarins from grapefruit extract,
CYP2D6 inhibition is achieved in the range of 190-900 nM. As the tested anthocyanins and
anthocyanidins were shown to be about 1,000-fold less potent, they are unlikely to interfere with drug
metabolism by CYP2D6. Further studies are warranted to examine the effects of the above flavonoids
on other CYP isoforms for more detailed toxicity profiles.
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Background 
The cytochrome P450 CYP2D6 isoform is involved in the metabolism of about 50% of all 
psychoactive drugs, including neuroleptic agents, selective serotonin reuptake inhibitors 
(SSRIs), selective norepinephrine reuptake inhibitors (SNRIs) and tricyclic antidepressants 
(TCAs). Therefore, inhibition of cytochrome P450 by foodstuffs has implications for drug 
safety. The present study addresses inhibitory effects of polyphenolic anthocyanins and their 
aglycons that are found in many dietary fruits and vegetables.  
Methods 
Following incubation of membrane preparations containing recombinant human CYP2D6 
enzyme with anthocyanins and their aglycons, inhibition of enzyme activity was determined 
using a chemiluminescent assay. 
Results 
Both anthocyanins and their aglycons, the anthocyanidins, inhibited CYP2D6 activity in a 
concentration-dependent manner with IC50 values ranging from 55 µM, for the anthocyanidin 
pelargonidin, to over 800 µM for diglycoside anthocyanins pelargonin and cyanin. 
Conclusions 
According to earlier data on furanocoumarins from grapefruit extract, CYP2D6 inhibition is 
achieved in the range of 190 to 900 nM. In comparison, the tested anthocyanins and 
anthocyanidins were shown to be about 1000-fold less potent, and unlikely to interfere with 
drug metabolism by CYP2D6. However, further studies are invited to examine effects of the 
above flavonoids on other CYP isoforms for more detailed toxicity profiles. 
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Cytochrome P450 enzymes represent a large family of microsomal heme-containing 
monooxygenase isoenzymes that are expressed on smooth endoplasmic reticulum membranes 
by liver hepatocytes, and by cells along the intestinal tract mucosal surface 1. They catalyze 
the detoxification of a wide variety of xenobiotics such as drugs, biogenic amines derived 
from food sources, environmental toxins and chemical carcinogens, plus the oxidation of 
endogenous substances like steroids, fatty acids, prostaglandins and leukotrienes 2,3. In 
addition, some isoforms have been implicated in the activation of procarcinogens 4,5. 
Within the P450 super-family, the cytochrome P450 2D6 (CYP2D6) plays a key role in the 
metabolism of centrally acting drugs, including many neuroleptics 6, selective serotonin 
reuptake inhibitors (SSRIs) 7, selective norepinephrine reuptake inhibitors (SNRIs) 8 and 
tricyclic antidepressants (TCAs) 9, by hydroxylation 10, demethylation 11 or 
dealkylation reactions 3. The human brain’s CYP2D6 expression pattern maps to the 
dopaminergic system 12 where CYP2D6 converts the endogenous substrate tyramine, which 
is formed from tyrosine or phenylalanine, to dopamine. This implies that inhibitors may alter 
tyrosine and dopamine levels via brain CYP2D6. 
During treatment with psychoactive drugs, CYP2D6 inhibitors from food sources may 
provoke adverse effects and limit the use of medication. Interactions with enzyme inhibitors 
have been shown to affect both pharmacokinetic and pharmacodynamic parameters of drugs 
13,14, and to augment drug toxicity 15. In an estimated 10% of the general population, 
CYP2D6 substrate metabolism may be seriously compromised owing to an innate deficiency 
in enzymatic activity 16,17.  
The opportunity for a food-drug interaction is an everyday occurrence, of which grapefruit 
juice provides a prominent example. Coadministration of grapefruit juice with many 
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therapeutic agents is known to increase the oral bioavailability of common drugs by altering 
presystemic metabolism, particularly in the intestine 18. Compounds from grapefruit juice 
that exhibit cytochrome P450 inhibitory activity include furanocoumarins and the flavonoids 
naringin, quercetin and kaempferol 15. Inhibitory compounds are equally found in black 
raspberry juice, wild grape juice, black mulberry juice 19, red wine 20 and, presumably, in 
cranberry juice 21. Recognition of such drug-food interactions has raised concerns over 
risks that may be posed by functional foods, and specifically, by food enriched with 
secondary plant metabolites.  
Among the phenolic compounds for which P450 inhibitory activity is still unknown count 
anthocyanins. These water-soluble glycosidic derivates of flavylium salts occur in different 
pH-dependent conformations and are most abundant in berries, grapes and red cabbage, 
among other foodstuffs 22. When expressed per 100 g fresh weight, approximately 1480 mg 
of anthocyanins may be obtained from chokeberries 23, 588 mg from bilberries 24, 476 
mg from black currant, and 322 mg from red cabbage 23. The average dietary per capita and 
day consumption of anthocyanins was originally estimated at 180 – 215 mg in Western 
societies 25. More recent calculations from U.S. American surveys have concluded to a 
daily intake of only 12.5 mg 23 but the actual amount has been shown to vary considerably 
with sociodemographic and life-style factors 26, plus the seasonal availability of 
anthocyanin-rich fruits and vegetables 23. 
In recent years, numerous studies have testified to anthocyanins’ health benefits, greatly 
promoting their popularitiy. Favourable effects have been described on free radical 
scavenging and antioxidant systems 27,28,29, on immune defense 30, on inflammation 
31,32, on sensory functions 33,34, and on parameters of neuroprotection 35,36,37. It has 
been shown that anthocyanins themselves are not metabolized by cytochrome P450 enzymes 
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38 but their ability to interfere with the metabolism of centrally acting drugs via inhibition 
of CYP2D6 has not been examined.  
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Chemicals 
P450-GloTM screening system was purchased from Promega (Mannheim, Germany). 
Quinidine was obtained from Sigma-Aldrich (Schnelldorf, Germany).  
Cyanidin, cyanidin-3,5-diglucoside (cyanin), cyanidin-3-galactoside (ideain), cyanidin-3-
glucoside (kuromanin), cyanidin-3-rutinoside (keracyanin), delphinidin, delphinidin-3-
glucoside (myrtillin), malvidin, malvidin-3,5-diglucoside (malvin), malvidin-3-galactoside, 
malvidin-3-glucoside (oenin), peonidin, peonidin-3-glucoside, pelargonidin, pelargonidin-3,5-
diglucoside (pelargonin), petunidin, and procyanidin B2 were purchased from Extrasynthese 
(Genay, France). All test substances were dissolved and diluted in DMSO. 
 
CYP2D6 Assay 
Effects of test substances on CYP2D6 activity were determined using a validated and 
isoenzyme-specific screening system (P450-GloTM) 39 according to the manufacturer’s 
protocol. At room temperature, a membrane preparation, containing recombinant human 
CYP2D6 and cytochrome P450 reductase, was preincubated for 10 minutes with the 
compound under study and the ethylene glycol ester of luciferin-6’-methylether (luciferin-ME 
EGE), a luminogenic substrate. The assay was perfomed in 96-well microtiter plates in KPO4 
buffer. NADP+, glucose-6-phosphate, MgCl2, and glucose-6-phosphate dehydrogenase served 
as a NADPH regeneration system, and were added to start the enzymatic reaction. Final 
concentrations in the assay were 0.25 pmol CYP2D6, 100 mM KPO4, 30 µM luciferin-ME 
EGE, 1.3 mM NADP+, 3.3 mM glucose-6-phosphate, 3.3 mM MgCl2, 0.4 U/ml glucose-6-
phosphate dehydrogenase, and 50 µM sodium citrate. Subsequent to incubation at room 
temperature for 45 min, the reaction was stopped and a luminescent signal was initiated by 
adding a detection reagent, containing an esterase and a firefly luciferase. After another 20 
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minutes, chemiluminescence values, displayed as relative light units (RLU), were recorded on 
an Anthos Lucy 1 microplate luminometer (Anthos Labtech, Salzburg, Austria) with a 
measuring time of 12 s for each well.  
Anthocyanins, anthocyanidins and procyanidin B2 were diluted with DMSO to yield final 
concentrations ranging from 20 to 800 µM in the assay. Quinidine was diluted to final 
concentrations of 1, 10, 100 and 1000 nM.  
 
Data analysis 
For quantification of CYP2D6 inhibition, enzyme activity was calculated using the light 
signal generated by oxidation of luciferin which, in turn, is produced by CYP2D6 
demethylation of the substrate luciferin-ME EGE. As the amount of light is directly 
proportional to the amount of luciferin released in the reaction with CYP2D6, the following 
equation applies: 



 
DMSO
I
A
AA 1100%  142 
143 
144 
145 
146 
147 
148 
149 
150 
151 
152 
153 
where %A is the percentage of CYP2D6 activity remaining after the exposure to test 
substances, AI  is the activity in the presence of an inhibitor, and ADMSO  is the enzyme activity 
in the absence of inhibitors (control). 
For each substance tested, mean values were analyzed from three separate experiments 
performed in triplicate at up to five concentrations steps, using a non-linear regression model 
to determine the concentration inhibiting 50% of maximum CYP2D6 activity (Prism v. 2.01, 
GraphPad Software, CA, USA). For assessing possible effects of structural features 
(anthocyanin sugar moiety and substitution pattern of the flavonoids’ B-ring) on CYP2D6 
inhibition, we performed analysis of variance (ANOVA) (Stata 8, Stata Corp., College 
Station, TX, USA). Statistical significance was set at p = 0.05. ISIS/Draw v. 2.1.4 (MDL 
Information Systems, CA, USA) served to illustrate structures of anthocyanidins.  
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In total, modulatory effects of sixteen anthocyanins and anthocyanidins on cytochrome P450 
2D6 activity were investigated, plus effects of the natural anthocyanin precursor procyanidin 
B2, an epicatechin-epicatechin dimer (figure 1). IC50 values of all flavonoids under study are 
summarized in table 1. Test compounds inhibited CYP2D6 activity in a concentration-
dependent manner with IC50 values starting at 55 µM (pelargonidin), and exceeding 800 µM 
(diglucosides of cyanidin and pelargonidin, procyanidin B2).   
The four most potent inhibitors were the anthocyanidins pelargonidin, peonidin, delphinidin 
and cyanidin, with IC50 values of 55, 59, 66, and 69 µM, respectively. For the remaining 
anthocyanidins, IC50 values of 77 (malvidin) and 150 µM (petunidin) were determined. 
Regarding the tested anthocyanins, IC50 values from 70 to 266 µM were obtained in the order 
of decreasing potency for malvidin-3-glucoside, malvidin-3-galactoside, delphinidin-3-
glucoside, malvidin-3,5-diglucoside, cyanidin-3-glucoside, peonidin-3-glucoside, cyanidin-3-
galactoside, and cyanidin-3-rutinoside. Finally, the least potent inhibitors were identified as 
the diglucosidic anthocyanins pelargonidin-3,5-diglucoside, plus cyanidin-3,5-diglucoside 
and procyanidin B2, all of which featured IC50 values greater than 800 µM. Quinidine, a 
widely used inhibitor that had been chosen for a reference, reached an IC50 value of 6 nM.  
To investigate the modulatory effects of substances’ sugar moiety or B-ring substitution 
pattern, analysis of variance (ANOVA) was performed, excluding cyanidin-3,5-diglucoside 
and pelargonidin-3,5-diglucoside, for which IC50 values could not be calculated (> 800 µM).  
When only presence vs. absence of the sugar moiety was used to predict IC50 values, the 
model reached significance (p = 0.03, F = 5.7, R2 = 0.32). Fitting was improved when the 
number of B-ring substituents, plus an interaction term (sugar moiety*substituents) were 
included in the model (p = 0.006, F = 7.73, R2 = 0.78). Specifically, anthocyanins were shown 
to be weaker CYP2D6 inhibitors than anthocyanidins (table 1), and CYP2D6 inhibition 
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decreased with more substituents on anthocyanidins’ B-ring, whereas it increased with more 
substituents on anthocyanins’ B-ring. 
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Dietary supplementations with anthocyanin-rich fruit extracts have been advocated in the 
light of multiple health-promoting effects including antioxidant, anti-inflammatory, and 
neuroprotective activities 40,41,42,43,44. However, limited data exist on possible adverse 
effects as a consequence of food-drug interactions. Foods that contain complex mixtures of 
phytochemicals, such as fruits, vegetables, herbs, spices and teas have great potential to 
induce or inhibit the activity of drug-metabolizing enzymes, including cytochrome P450 
enzymes 45,46. Such interactions are exemplified by effects of grapefruit juice, red wine, 
black mulberry juice and black raspberry juice 13,15,18,19,20,47,48,49. Amidst growing 
safety concerns, the present study addresses in vitro interactions with CYP2D6, an isoform 
highly relevant to the metabolism of many psychoactive drugs 17,50,51,52,53. In 
continuation of earlier studies with grapefruit extract 15 and the polyphenolic apple 
constituent quercetin 54,55, CYP2D6 activity was determined in the presence of 
anthocyanins, the corresponding aglycons, and the procyanidin dimer B2. 
Our data show that anthocyanins and anthocyanidins are weak inhibitors of CYP2D6, with 
IC50 values in the micromolar range, starting at 55 µM and exceeding 800 µM for several 
compounds. When anthocyanins and anthocyanidins were compared, mean inhibitory potency 
of anthocyanins was lower (p = 0.03, F = 5.7, R2 = 0.32). Of all molecules under study, 
diglucosides of cyanidin and pelargonidin, plus procyanidin B2 exhibited the weakest effects.  
Analysis of variance confirmed a modulatory role of the B-ring substitution pattern (number 
of substituents), plus the interaction term (sugar moiety*substituents). Anthocyanidins with 
three hydroxyl- or methoxyl-substituents on their B-ring acted as weaker inhibitors than did 
agents with fewer substituents. In contrast, anthocyanidin-3-glycosides and anthocyanidin-
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3,5-diglycosides achieved lower IC50 values when the B-ring was substituted to a greater 
extent.  
Only few data are available on CYP2D6 inhibitory effects of defined polyphenolic 
compounds. Of these, quercetin exhibited an IC50 value of 24 µM 55, while flavonols and 
flavonol glycosides from wild ginger exhibited IC50 values ranging from 5 to 51 µM 56. In 
contrast, furanocoumarins from grapefruit juice achieved 50% inhibition in the nanomolar 
range. Specifically, bergamottin, 6’,7’-dihydroxybergamottin (DHB) and the dimerics GF-I-1 
(4-[[6-hydroxy-7-[[1-[(1-hydroxy-1-methyl)ethyl]-4-methyl-6-(7-oxo-7H-furo[3,2-
g][1]benzopyran-4-yl)-4-hexenyl]oxy]-3,7-dimethyl-2-octenyl]oxy]-7H-furo[3,2-
g][1]benzopyran-7-one) and GF-I-4 (4-[[6-hydroxy-7-[[4-methyl-1-(1-methylethenyl)-6-(7-
oxo-7H-furo[3,2-g][1]benzopyran-4-yl)-4-hexenyl]oxy]-3,7-dimethyl-2-octenyl]oxy]-7H-
furo[3,2-g][1]benzopyran-7-one) reached IC50 values of 190 nM, 900 nM, 200 nM and 300 
nM, respectively 15. For comparison, psychoactive drugs have yielded CYP2D6 IC50 values 
of 1.2 (paroxetine), 1.5 (perphenazine), 2.7 (thioridazine) and 6.5 nM (haloperidol) 57,58,59 
(figure 2). 
Inhibitory effects of anthocyanins on CYP2D6 are weaker by several orders of magnitude, 
ranging from 70 µM to over 800 µM. According to in silico prediction models, structural 
features required for effective CYP2D6 inhibition comprise a tertiary amine fragment plus a 
positive charge on nitrogen and flat hydrophobic region 60. These ligand descriptors are not 
met by the compounds investigated here, and relative to the cinchona alkaloid quinidine, the 
inhibitory potential of anthocyanins and their aglycons was at least 10 000-fold lower. This 
suggests that anthocyanins pose a limited risk of food-drug interactions mediated by CYP2D6 
as compared to above mentioned grapefruit and apple constituents, or other phytochemicals. 
For an extrapolation of in vitro data to in vivo effects, additional parameters must be taken 
into account. Thus it has been proposed that CYP2D6 may be less susceptible to inhibition by 
food constituents than other isoforms, since substances must cross the intestinal barrier before 
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they can act on hepatic CYP2D6, whereas high-level expression of other cytochromes in the 
intestine allows interactions during digestion 61. Depending on anthocyanins’ in vivo portal 
availability which has yet to be determined, the impact on metabolic processes may be even 
smaller than anticipated.  
Clinical relevance of CYP450 inhibition is subject to individual differences in enzyme 
activity, i.e. the prevalence of functional genetic variants. The present data obtained with 
recombinant human CYP2D6 count against CYP2D6 modulatory effects of anthocyanins and 
anthocyanidins for subjects carrying the CYP2D6*1 allele 62, i.e. for the majority of the 
Caucasian population. Whether similar effects can be expected in carriers of other CYP2D6 
alleles remains to be determined.  
Finally, characterization of anthocyanin effects on additional CYP450 isoforms is invited to 
foster our understanding of polyphenolics’ biological activity. Thus inhibitors of 
procarcinogen-activating isoforms (e.g., CYP19, CYP1A or CYP1B) may limit the generation 
of harmful metabolites from estradiol 5, aromatic amines, heterocyclic amines 4, and 
polycyclic aromatic hydrocarbons 5. More detailed toxicity profiles will help to unveil the 
related benefits and novel dietary or medical applications of anthocyanins. 
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Anthocyanin-rich extracts from berry fruits have become popular food supplements 
warranting investigations of possible interactions with drug metabolism. The present in vitro 
study argues against such interactions with regard to metabolism by the human cytochrome 
2D6 isoenzyme. In comparison to established enzyme inhibitors, the flavonoids examined 
proved weaker by several orders of magnitude. However, further studies are invited to 
examine effects of anthocyanins on other CYP isoforms for more detailed toxicity profiles. 
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Table 1.  Inhibition of CYP2D6 activity by anthocyanins and anthocyanidins and mean IC50 values.  
 
anthocyanin/anthocyanidin IC50 in µM (anthocyanidins)
IC50 in µM 
(anthocyanins) 
pelargonidin 55  [51 - 59]   
peonidin 59 [51 - 67]   
delphinidin 66 [65 - 68]   
 14
cyanidin 69 [64 - 74]   
malvidin-3-glucoside (oenin)   70 [68 - 72] 
malvidin-3-galactoside   73 [67 - 80] 
malvidin 77 [69 - 85]   
delphinidin-3-glucoside (myrtillin)   109 [87 - 137] 
malvidin-3,5-diglucoside (malvin)   145 [133 - 157] 
petunidin 150 [138 - 162]   
cyanidin-3-glucoside (kuromanin)   151 [114 - 199] 
peonidin-3-glucoside   217 [199 - 237] 
cyanidin-3-galactoside (ideain)   245 [217 - 278] 
cyanidin-3-rutinoside (keracyanin)   266 [169 - 420] 
mean IC50 value +/ SD 79 +/ 32 160 +/ 71 
277 
278 
279 
280 
281 
282 
283 
284 
 
95% confidence intervals are given in brackets. Procyanidin B2, plus the anthocyanins pelargonidin-3,5-
diglucoside (pelargonin) and cyanidin-3,5-diglucoside (cyanin) lacked CYP2D6 inhibitory activity (IC50 > 800 
µM). 
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Figures 
 
Figure 1 – Chemical structures 
Chemical structures of tested anthocyanidins (A) and procyanidin B2 (B),  
an epicatechin-epicatechin dimer. 
 
Figure 2 – IC50 values of anthocyanins, anthocyanidins, psychoactive drugs 
(haloperidol, thioridazine, perphenazine, paroxetine), furanocoumarins (bergamottin, 
6’,7’-DHB, GF-I-1, GF-I-4) and quinidine. 
Only those compounds are shown for which IC50 values were available, i.e. excluding 
cyanidin-3,5-diglucoside and pelargonidin-3,5-diglucoside. 
 
Table 
Table 1 - Inhibition of CYP2D6 activity by anthocyanins and anthocyanidins and mean 
IC50 values 
95% confidence intervals are given in brackets. Procyanidin B2, plus the anthocyanins 
pelargonidin-3,5-diglucoside (pelargonin) and cyanidin-3,5-diglucoside (cyanin) lacked 
CYP2D6 inhibitory activity (IC50 > 800 µM). 
